Idiopathic Pulmonary Fibrosis Clinical Trials

55 recruiting

Idiopathic Pulmonary Fibrosis Trials at a Glance

69 actively recruiting trials for idiopathic pulmonary fibrosis are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 2 with 22 trials, with the heaviest enrollment activity in Kansas City, Birmingham, and Los Angeles. Lead sponsors running idiopathic pulmonary fibrosis studies include Avalyn Pharma Inc., Boehringer Ingelheim, and Seoul National University Hospital.

Browse idiopathic pulmonary fibrosis trials by phase

Treatments under study

About Idiopathic Pulmonary Fibrosis Clinical Trials

Looking for clinical trials for Idiopathic Pulmonary Fibrosis? There are currently 55 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Idiopathic Pulmonary Fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Idiopathic Pulmonary Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 69 trials

Recruiting
Phase 2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim71 enrolled47 locationsNCT07036523
Recruiting
Phase 2

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim20 enrolled3 locationsNCT06241560
Recruiting
Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled371 locationsNCT06238622
Recruiting
Not Applicable

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Assiut University30 enrolled2 locationsNCT05842681
Recruiting
Phase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.340 enrolled52 locationsNCT06951217
Recruiting
Phase 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics120 enrolled9 locationsNCT06968845
Recruiting
Phase 3

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

Idiopathic Pulmonary Fibrosis (IPF)
Sunshine Lake Pharma Co., Ltd.472 enrolled1 locationNCT07082842
Recruiting
Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Mannkind Corporation24 enrolled8 locationsNCT07344558
Recruiting
Phase 1

NAL ER IPF Respiratory Function and Safety Study

Idiopathic Pulmonary Fibrosis
Trevi Therapeutics10 enrolled2 locationsNCT07036029
Recruiting
Phase 2

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
AbbVie165 enrolled6 locationsNCT07230288
Recruiting
Not Applicable

Validation of the C-mo System - Cough Monitoring

AsthmaChronic Obstructive Pulmonary DiseaseIdiopathic Pulmonary Fibrosis+5 more
Cough Monitoring Medical Solutions300 enrolled8 locationsNCT05989698
Recruiting
Phase 2

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.160 enrolled3 locationsNCT07194382
Recruiting
Phase 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Mediar Therapeutics164 enrolled65 locationsNCT06967805
Recruiting
Phase 2

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Calluna Pharma AS150 enrolled54 locationsNCT06736990
Recruiting
Phase 3

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary FibrosisAcute Exacerbation of Idiopathic Pulmonary Fibrosis
Argyrios Tzouvelekis196 enrolled1 locationNCT07299695
Recruiting
Phase 2

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB360 enrolled117 locationsNCT06588686
Recruiting
Phase 3

A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)
Beijing Tide Pharmaceutical Co., Ltd508 enrolled1 locationNCT07464912
Recruiting
Early Phase 1

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Idiopathic Pulmonary Fibrosis
Shanghai Synvida Biotechnology Co.,Ltd.53 enrolled1 locationNCT06267183
Recruiting
Not Applicable

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Fibrotic Interstitial Lungs Diseases
Katerina M. Antoniou100 enrolled1 locationNCT07466420
Recruiting
Phase 2

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Cumberland Pharmaceuticals128 enrolled19 locationsNCT05571059